News Wire ~ 3rd Party Press Release
Researchers Develop First Functional Targeted Inhibitors of Peanut Allergens
“The success of this study is exciting because it opens the door to establishing an entirely new class of allergy therapeutics."
Snap Medical Announces EMS-Designed Epinephrine Delivery Kit
Kit can be assembled and ready for administration in 25 seconds.
European Phase 3 Trial of AR101 Peanut OIT Candidate Meets Primary Endpoint
Company Intends to Submit European MAA in Mid-2019.
AAP Clinical Report Highlights Early Introduction of Peanut-Based Foods to Prevent Allergies
The American Academy of Pediatrics updates a clinical report that explores how maternal and infant nutrition affect development of infant allergies.
US FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition.
State Legislation Would Provide Epinephrine Auto-Injectors at No Cost to Patients
Bill named 'An Act To Save Lives through Epinephrine Autoinjector Accessibility'.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Patent Granted for Toothpaste Immunotherapy for Food Allergy
The patent includes claims to the approach of combining allergenic proteins with toothpaste.
AllergyEats Announces 2019 List of Top 10 Most Allergy-Friendly Restaurant Chains in America
Regionally diverse list illustrates growing trend to better accommodate food-allergic diners nationwide.
Egg OIT Leads to More Rapid Allergy Desensitization Than Baked-Egg Products
Study suggests oral immunotherapy may lead to higher sustained unresponsiveness to egg for baked-egg tolerant children.
